High-Barrier Film Active Packaging Patents: Trends & White Space 2026
- Filing peaked in 2019 at 11 families and has since drifted back toward the 2017 starting level, a flat-to-declining trend rather than an accelerating one.
- B32B laminate claims dominate the corpus appearing in 120 of 131 families, while pharmaceutical-adjacent classes (A61J, A61K, C07K) each sit at 34 — a sizeable but secondary cluster.
- Citation weight concentrates in older hemoglobin-preservation art three of the five most-cited records trace back to a single blood-substitute overwrap lineage, not to recent active-barrier filings.
Filing growth compares 2021 (1 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 131 records in scope (CR5), not by the ranked leaders only.
What this dataset covers
The search combines barrier-film terminology with active-packaging function terms — oxygen scavenger, active barrier, antimicrobial packaging, moisture absorber — restricted to three IPC anchors covering packaging containers, layered laminates and food preservation. That combination pulls in 131 patent families published between 2015 and mid-2026, spanning both consumer food packaging and medical/pharmaceutical containment.
Because publication typically lags filing by around 18 months, the most recent one or two years in the trend chart will always understate actual filing activity; treat the tail of the chart as incomplete rather than as a genuine drop-off.
Filing trend and technology composition
Two views of the same 131 families: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
A peak in 2019, then a plateau
Filings rose from 4 in 2017 to a peak of 11 in 2019, fell back to 3 by the 2022 midpoint, and show no renewed acceleration through the most recent complete years. This is a mature, flat-to-declining filing pattern rather than an emerging one — new entrants are filing into a field whose growth phase has already passed, at least on the evidence available so far.
Laminates dominate; medical uses are a real secondary cluster
B32B (layered products) touches 120 of 131 families and B65D (containers) 75, confirming the core is film/laminate construction rather than the active-agent chemistry itself. A61J, A61K and C07K each register 34 records, pointing to a distinct medical-packaging and biologic-preservation branch — visible in the hemoglobin blood-substitute prior art — that runs alongside, rather than inside, the food-packaging mainstream.
Shares are the percentage of the 131 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on High-Barrier Film Active Packaging with Eureka
This page is one run against one query. Ask Eureka your own question about high-barrier film active packaging and every answer comes back with the patent numbers behind it.
Try EurekaA representative grant and the most-cited prior art
CA2693619C — Packaging with IML barrier film in combination with an oxygen scavenger
The invention relates to a packaging article for containing and holding food products, which article comprises barrier means for limiting permeability of oxygen through the article and into the one or more chambers, where the packaging article comprises oxygen scavenging means, which together with a second plastic material is moulded into a cavity in a first plastic material forming walls, bottom(s) and lid(s) of the packaging article, which first plastic material is suitable for contact with food products.Filed by SUPERFOS A/S; granted 2015-10-13. Claims an in-mould-labelled barrier film combined with an integral oxygen scavenger produced within a single injection-moulding cycle.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20070264520A1 | Articles having a polymer grafted cyclodextrin | 168 |
| 2 | US7041800B1 | Preserving a hemoglobin blood substitute with a transparent overwrap | 48 |
| 3 | WO2014161653A1 | Container for a food, beverage or pharmaceutical product an method of preparation thereof | 42 |
| 4 | US20060160724A1 | Preserving a hemoglobin blood substitute with a transparent overwrap | 28 |
| 5 | WO2000021366A1 | Method for preserving a hemoglobin blood substitute | 23 |
| 6 | US20110229701A1 | Multilayer Active Oxygen Barrier Film Comprising a Plurality of Microlayers | 18 |
| 7 | JP2002065808A | Package for stably preserving plastic vessel holding medical solution containing amino acid | 17 |
| 8 | JP2003292055A | Container | 15 |
| 9 | WO2001001775A1 | Preserving a hemoglobin blood substitute with a transparent overwrap | 14 |
| 10 | WO1998024625A1 | Multilayer, high barrier film | 14 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this searched corpus; read them as a signal of influence on the field's vocabulary, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-outs from the trend, class composition and citation data, translated into what they imply for someone deciding where to file or design around.
Growth has already flattened
The jump to 11 families in 2019 followed by a retreat to 3 by 2022 indicates this is not a rising field to race into; it is a settled one where remaining opportunity sits in specific gaps rather than in broad claims.
Laminate construction is the crowded layer
Nearly every family in this set makes a layered-product claim, meaning generic barrier-film-plus-scavenger constructions are heavily occupied. Differentiation is more likely to survive in the active-agent chemistry or in the medical-packaging branch than in laminate architecture alone.
Influence sits outside the mainstream food-packaging thread
The most-cited records in this corpus are dominated by a hemoglobin blood-substitute preservation lineage, not by consumer food-packaging filings. That lineage shaped preservation-barrier vocabulary broadly but is a poor proxy for what is commercially active in food packaging today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to high-barrier film active packaging, with the prior art for and against each one.
Who is filing, and where the activity has gone quiet
Recent-year momentum across the named assignees in this dataset reads as zero across the board — a signal that this field's active filers have paused rather than accelerated, and that credited inventors from the earlier blood-substitute lineage account for a meaningful share of the co-filing structure.
A broad but thinly active roster
The assignee ranking spans consumer packaging converters, gas-barrier chemical makers and individual inventors tied to medical preservation patents, with no single filer showing renewed activity in the latest year.
A tight inventor cluster around blood-substitute preservation
The strongest co-assignee pairs — each appearing together 5 times — link three named inventors associated with hemoglobin blood-substitute preservation art, a self-contained sub-cluster distinct from the food-packaging converters in the same dataset.
Europe leads receipt, with a notable New Zealand presence
The EPO is the largest single receiving office, ahead of the United States, with New Zealand's 13 filings an unusually strong showing for a market of its size — worth checking against any specific regional freedom-to-operate question.
| Assignee | Recent year | YoY |
|---|---|---|
| Bericap | 0 | — |
| Superfos A/S | 0 | — |
| Cryovac, Inc. | 0 | — |
| Mitsubishi Gas Chemical Company, Inc. | 0 | — |
| LIGHT WILLIAM R | 0 | — |
| HOUTCHENS ROBERT A | 0 | — |
| GAWRYL MARIA S | 0 | — |
| Tetra Laval Holdings & Finance S.A. (Switzerland) | 0 | — |
Where to take this analysis
The dataset points to a mature filing pattern with a specific under-claimed medical-packaging branch. These are reasonable next steps depending on what decision is in front of you.
Check freedom-to-operate against the laminate core
With 120 of 131 families touching B32B, any new barrier-film-plus-active-agent design should be checked against the densest layer of this corpus before investing in prototyping.
Run a claim search in Patsnap Eureka →Scope the medical-packaging branch separately
A61J, A61K and C07K form a distinct 34-record cluster tied to biologic preservation rather than food packaging — worth its own targeted search if that is the actual application.
Explore this branch in Patsnap Eureka →Re-run the trend after the next publication cycle
Because the last one to two years are understated by publication lag, a fresh pull in six to twelve months will give a truer read on whether 2022's decline has continued.
Set up a monitoring search in Patsnap Eureka →Common questions about this landscape
In this dataset, a record must combine barrier-film terminology (high-barrier film, barrier film, high barrier packaging film) with an active-packaging function term such as oxygen scavenger, active barrier, antimicrobial packaging or moisture absorber, and it must fall under at least one of three IPC anchors covering packaging containers, layered laminates, or food preservation methods. This combination deliberately excludes plain passive barrier films that make no active-function claim. It also pulls in some medical and pharmaceutical containment patents that use the same barrier-plus-active-agent structure, which is why classes like A61J and A61K appear alongside the food-packaging core.
Based on the data through the most recent complete years, filing activity peaked in 2019 at 11 families and had fallen back to 3 by the 2022 midpoint, with no sign of renewed acceleration. That reads as flat-to-declining rather than growing. The most recent one to two years should be treated cautiously, since publication typically lags filing by around 18 months, so any apparent further drop at the very end of the chart is partly an artefact of that lag rather than a confirmed trend.
The laminate construction layer (B32B) is heavily occupied, appearing in 120 of 131 families, so a claim built purely around film architecture faces dense prior art. Lower documented density shows up in specific combinations: antimicrobial coatings applied to injection-moulded barrier film, moisture-absorber sachets integrated into rigid trays, and active-barrier claims paired with particular polymer compositions or medicinal-device containment uses. These narrower combinations are worth a dedicated novelty search before committing to drafting.
CA2693619C, granted to SUPERFOS A/S in 2015, claims a packaging article combining an in-mould-labelled barrier film with an oxygen-scavenging means, where both the scavenger and a second plastic material are moulded into a cavity within a first food-contact-safe plastic material in a single injection-moulding cycle. It is representative of the corpus's core approach rather than uniquely dominant, but anyone designing a similarly integrated single-shot moulded barrier-plus-scavenger package should review its specific claim language on cavity formation and process sequencing. Designs that apply the scavenger post-mould, or use a separate lamination step rather than co-moulding, sit further from this claim scope.
Citation weight in this corpus concentrates in an older hemoglobin blood-substitute preservation lineage, with the most-cited record reaching 168 citations for a cyclodextrin-grafted polymer article, and several other top-cited records tracing to a shared overwrap-preservation invention. Three named individual inventors tied to that lineage form the strongest co-assignee pairing in the dataset. This historical influence should not be read as current commercial dominance — recent-year filing momentum across all named assignees in this dataset, including that cluster, sits at zero.
Research High-Barrier Film Active Packaging in depth with Eureka
Go past this page: query the whole high-barrier film active packaging corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.